Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , |
| Tipo de documento: | Artigo de conferência |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da UNESP |
| Texto Completo: | http://hdl.handle.net/11449/218642 |
Resumo: | Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil |
| id |
UNSP_535ea29cead4659f3a11423a634fd0ba |
|---|---|
| oai_identifier_str |
oai:repositorio.unesp.br:11449/218642 |
| network_acronym_str |
UNSP |
| network_name_str |
Repositório Institucional da UNESP |
| repository_id_str |
2946 |
| spelling |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in BrazilUniv Fed Rio Grande do Sul, Porto Alegre, RS, BrazilHosp Clinicas Porto Alegre, Porto Alegre, RS, BrazilUniv Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, BrazilInst Dermatol & Aesthet Rio Janeiro, Rio De Janeiro, BrazilUniv Sao Paulo, Hosp Clin, Dept Dermatol, Sao Paulo, BrazilHosp Moinhos Vento, Porto Alegre, RS, BrazilPontif Univ Catolic Parana, Discipline Dermatol, Curitiba, Parana, BrazilSao Paulo State Univ UNESP, Botucatu Sch Med, Dept Dermatol & Radiotherapy, Botucatu, SP, BrazilState Coll Med Sao Jose Rio Preto, Sao Jos Rio Preto, BrazilMackenzie Evangel Univ Hosp Curitiba Paran, Curitiba, Parana, BrazilAbbVie Deutschland GmbH & Co KG, Ludwigshafen, GermanyFac Med ABC, Sao Paulo, BrazilSao Paulo State Univ UNESP, Botucatu Sch Med, Dept Dermatol & Radiotherapy, Botucatu, SP, BrazilElsevier B.V.Univ Fed Rio Grande do SulHosp Clinicas Porto AlegreUniversidade de São Paulo (USP)Inst Dermatol & Aesthet Rio JaneiroHosp Moinhos VentoPontif Univ Catolic ParanaUniversidade Estadual Paulista (UNESP)State Coll Med Sao Jose Rio PretoMackenzie Evangel Univ Hosp Curitiba ParanAbbVie Deutschland GmbH & Co KGFac Med ABCCestari, Tania F.Souza, Cacilda daSilvaAzulay-Abulafia, LunaRomiti, RicardoCarvalho, Andre V. E.Silva de Castro, Caio CesarMarques, Silvio Alencar [UNESP]Antonio, Joao RobertoFabricio, LincolnKalabic, JasminaOyafuso, Luiza Keiko2022-04-28T17:22:06Z2022-04-28T17:22:06Z2021-09-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectAB88-AB88Journal Of The American Academy Of Dermatology. New York: Mosby-elsevier, v. 85, n. 3, p. AB88-AB88, 2021.0190-9622http://hdl.handle.net/11449/218642WOS:000683887500345Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJournal Of The American Academy Of Dermatologyinfo:eu-repo/semantics/openAccess2024-08-14T18:46:48Zoai:repositorio.unesp.br:11449/218642Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T18:46:48Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
| dc.title.none.fl_str_mv |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil |
| title |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil |
| spellingShingle |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil Cestari, Tania F. |
| title_short |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil |
| title_full |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil |
| title_fullStr |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil |
| title_full_unstemmed |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil |
| title_sort |
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil |
| author |
Cestari, Tania F. |
| author_facet |
Cestari, Tania F. Souza, Cacilda daSilva Azulay-Abulafia, Luna Romiti, Ricardo Carvalho, Andre V. E. Silva de Castro, Caio Cesar Marques, Silvio Alencar [UNESP] Antonio, Joao Roberto Fabricio, Lincoln Kalabic, Jasmina Oyafuso, Luiza Keiko |
| author_role |
author |
| author2 |
Souza, Cacilda daSilva Azulay-Abulafia, Luna Romiti, Ricardo Carvalho, Andre V. E. Silva de Castro, Caio Cesar Marques, Silvio Alencar [UNESP] Antonio, Joao Roberto Fabricio, Lincoln Kalabic, Jasmina Oyafuso, Luiza Keiko |
| author2_role |
author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Univ Fed Rio Grande do Sul Hosp Clinicas Porto Alegre Universidade de São Paulo (USP) Inst Dermatol & Aesthet Rio Janeiro Hosp Moinhos Vento Pontif Univ Catolic Parana Universidade Estadual Paulista (UNESP) State Coll Med Sao Jose Rio Preto Mackenzie Evangel Univ Hosp Curitiba Paran AbbVie Deutschland GmbH & Co KG Fac Med ABC |
| dc.contributor.author.fl_str_mv |
Cestari, Tania F. Souza, Cacilda daSilva Azulay-Abulafia, Luna Romiti, Ricardo Carvalho, Andre V. E. Silva de Castro, Caio Cesar Marques, Silvio Alencar [UNESP] Antonio, Joao Roberto Fabricio, Lincoln Kalabic, Jasmina Oyafuso, Luiza Keiko |
| description |
Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-09-01 2022-04-28T17:22:06Z 2022-04-28T17:22:06Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/conferenceObject |
| format |
conferenceObject |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
Journal Of The American Academy Of Dermatology. New York: Mosby-elsevier, v. 85, n. 3, p. AB88-AB88, 2021. 0190-9622 http://hdl.handle.net/11449/218642 WOS:000683887500345 |
| identifier_str_mv |
Journal Of The American Academy Of Dermatology. New York: Mosby-elsevier, v. 85, n. 3, p. AB88-AB88, 2021. 0190-9622 WOS:000683887500345 |
| url |
http://hdl.handle.net/11449/218642 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Journal Of The American Academy Of Dermatology |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
AB88-AB88 |
| dc.publisher.none.fl_str_mv |
Elsevier B.V. |
| publisher.none.fl_str_mv |
Elsevier B.V. |
| dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
| instname_str |
Universidade Estadual Paulista (UNESP) |
| instacron_str |
UNESP |
| institution |
UNESP |
| reponame_str |
Repositório Institucional da UNESP |
| collection |
Repositório Institucional da UNESP |
| repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
| repository.mail.fl_str_mv |
|
| _version_ |
1808128185717489664 |